Vicarious Surgical (RBOT) Registration Filing summary

Company overview and business model

• Develops advanced miniaturized robotics and 3D visualization for single-port surgical robots aimed at minimally invasive procedures.

• Targets over 45 million annual soft tissue surgeries globally, with initial focus on ventral hernia procedures.

• System designed to address limitations of open and legacy robotic surgeries, offering improved dexterity and reduced trauma.

• Clinical-ready system expected by mid-2026, with first-in-human trials anticipated in 2027, pending regulatory clearance.

Financial performance and metrics

• No revenue from product sales to date; continues to incur significant losses as a development-stage company.

• Gross proceeds of approximately $5.9 million raised in October 2025 offerings, excluding potential warrant exercise proceeds.

• Classified as a smaller reporting company, providing reduced public disclosure and exempt from certain Sarbanes-Oxley requirements.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by the selling stockholder; proceeds from warrant exercises will be used for general corporate purposes, including working capital, capital expenditures, and R&D.

• Actual use of proceeds will depend on clinical trial scope, regulatory progress, and operational needs.